No Data Available
Speciality Medicines Share Price
BSE
Loading...
| Open | - |
| High | - |
| Low | - |
| Prev Close | - |
| Volume | - |
| VWAP(₹) | - |
Key Metrics
| PE Ratio(x) | - |
| EPS - TTM(₹) | - |
| MCap(₹ Cr.) | 178.35 |
| MCap Rank | 354 |
| PB Ratio(x) | 2.53 |
| Div Yield(%) | - |
| Face Value(₹) | 10.00 |
| 52W High(₹) | 381.20 |
| 52W Low(₹) | 121.10 |
| MCap/Sales | 1.47 |
| Beta(1 Month) | - |
| BV/Share(₹) | 81.03 |
Speciality Medicines share price insights
Employee & Interest Expense
Company has spent 1.75% of its operating revenues towards interest expenses and 2.3% towards employee cost in the year ending Mar 31, 2026. (Source: Standalone Financials)Speciality Medicines Share Price Update
Speciality Medicines Ltd. share price moved down by -0.73% from its previous close of Rs 204.50. Speciality Medicines Ltd. stock last traded price is 203.00
Share Price Value Today/Current/Last 203.00 Previous Day 204.50
Found Insights useful?
Speciality Medicines Share Price Returns
| 1 Day | -0.73% |
| 1 Month | -28.72% |
| 3 Months | N.A. |
| 1 Year | N.A. |
| 3 Years | N.A. |
| 5 Years | N.A. |
Speciality Medicines Share Recommendations
No Recommendations details available for this stock.
Check out other stock recos.
News & Analysis
Results - Financial Results For The Half Year And Year Ended March 31, 2026
AnnouncementsBoard Meeting Outcome for Outcome Of Board Meeting Held On Today I.E On May 28, 2026
AnnouncementsDisclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
AnnouncementsAnnouncement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
Announcements
Financials
Annual FY 2026 FY 2025 FY 2024 FY 2023 Total Revenue 76.11 58.54 27.66 23.26 Total Revenue Growth (%) 30.02 111.66 18.88 -42.48 Total Expenses 63.10 49.85 23.10 20.31 Total Expenses Growth (%) 26.57 115.79 13.73 -46.97 Profit after Tax (PAT) 13.03 8.61 2.93 1.69 PAT Growth (%) 51.40 193.43 73.70 14.16 Operating Profit Margin (%) 19.04 15.72 18.75 14.17 Net Profit Margin (%) 17.31 14.77 10.65 7.26 Basic EPS (₹) 20.11 14.10 7.07 4.72 InsightsEmployee & Interest Expense
Company has spent 1.75% of its operating revenues towards interest expenses and 2.3% towards employee cost in the year ending Mar 31, 2026. (Source: Standalone Financials)
Annual FY 2026 FY 2025 FY 2024 FY 2023 Total Assets 95.22 39.98 22.68 13.26 Total Assets Growth (%) 138.17 76.28 71.04 129.41 Total Liabilities 24.03 9.56 7.62 7.39 Total Liabilities Growth (%) 151.36 25.46 3.11 92.45 Total Equity 71.19 30.42 15.06 5.87 Total Equity Growth (%) 134.02 101.99 156.56 204.15 Current Ratio (x) 4.73 5.36 3.12 1.83 Total Debt to Equity (x) 0.09 0.17 0.19 0.62 Contingent Liabilities 0.00 - - - All figures in Rs Cr, unless mentioned otherwise
Annual FY 2026 FY 2025 FY 2024 FY 2023 Net Cash flow from Operating Activities -1.28 -5.79 -4.80 -4.21 Net Cash used in Investing Activities -2.83 -2.07 -0.03 0.03 Net Cash flow from Financing Activities 27.82 8.46 4.81 4.37 Net Cash Flow 23.70 0.60 -0.01 0.18 Closing Cash & Cash Equivalent 24.55 0.85 0.25 0.26 Closing Cash & Cash Equivalent Growth (%) 2,802.06 239.68 -4.78 240.49 Total Debt/ CFO (x) -5.19 -0.87 -0.60 -0.86 All figures in Rs Cr, unless mentioned otherwise
InsightsIncrease in Cash from Investing
Company has used Rs 2.83 cr for investing activities which is an YoY increase of 36.99%. (Source: Standalone Financials)
Annual FY 2026 FY 2025 FY 2024 FY 2023 Return on Equity (%) 18.30 28.30 19.47 28.77 Return on Capital Employed (%) 18.76 27.61 32.32 46.69 Return on Assets (%) 13.68 21.53 12.93 12.73 Interest Coverage Ratio (x) 11.00 19.80 8.92 10.49 Asset Turnover Ratio (x) 1.11 1.86 1.53 2.44 Price to Earnings (x) 8.49 - - - Price to Book (x) 1.55 - - - EV/EBITDA (x) 6.39 - - - EBITDA Margin (%) 19.27 16.06 19.59 15.44
Found Financials useful?
Technicals
No Data Available
R1 - Pivot -
S1 - R2 - S2 - R3 - S3 - 5 Days 14 Days 28 Days - - -
Peer Comparison
No Data Available
No Data Available
Mutual Funds Ownership
No Data Available
Speciality Medicines Top Searches
Corporate Actions
Board Meeting
Audited Results
May 21, 2026
Announced on Meeting on May 21, 2026 May 28, 2026 Audited Results No Data Available
No Data Available
No Data Available
No Data Available
No Data Available
About Speciality Medicines
Industry
Key Indices Listed On
BSE SME IPO
Address
913, One World West, S. No. 396, FP 119, Village- Vejalpur, AhmadAhmedabad, Gujarat - 380051
Executive Leadership
PG
Parthkumar Goyani
Chairman & Managing DirectorSG
Sumit Goyani
Whole Time DirectorBS
Bhaveshkumar Savani
Non Executive DirectorAB
Archana Bhayani
Independent DirectorShow More
Auditors
A K Ostwal & Co.
Top Gainers
As on 04:06 PM | 12 Jun 2026Top Losers
As on 03:58 PM | 12 Jun 2026Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.